Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 103 clinical trials
featured
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL), Lymphoplasmacytic Lymphoma(LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma(SMZL)

(MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these

lymphoma
chronic lymphocytic leukemia
lymphocytosis
lymphadenopathy
cancer
  • 89 views
  • 15 Apr, 2019
  • 1 location
A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R MZL will be evaluated in approximately 80 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.

  • 0 views
  • 03 Aug, 2021
  • 1 location
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).

  • 0 views
  • 27 Jun, 2021
  • 1 location
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28

  • 0 views
  • 01 Aug, 2021
  • 2 locations
High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection

gastric cancer, MALT lymphoma, and younger than 18 or older than 80 years old will be excluded. All patients will be naive to eradication therapy and will be randomized into one of three groups:

  • 0 views
  • 22 Jan, 2021
  • 1 location
MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Lymphoma (SMZL), up to 30, and Nodal Marginal Zone Lymphoma (NMZL), up to 15, will be included in the trial in order to preliminary explore the clinical activity and safety of the combination treatment

rituximab
gastric malt lymphoma
cytopenia
marginal zone lymphoma
remission
  • 51 views
  • 16 Jun, 2021
  • 54 locations
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

This is the study of the PI3K inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic

refractory follicular lymphoma
follicular lymphoma
marginal zone lymphoma
ct scan
ejection fraction
  • 127 views
  • 16 Apr, 2021
  • 145 locations
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.

  • 0 views
  • 01 Aug, 2021
  • 9 locations
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

This is a Phase 3 study of the PI3K inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL and MZL.

prednisone
rituximab
cyclophosphamide
measurable disease
bendamustine
  • 0 views
  • 13 Jun, 2021
  • 3 locations
Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (MK-1026-003)

lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenstrm's macroglobulinemia (WM).

leukemia
lymphoma
chronic lymphocytic leukemia
mantle cell lymphoma
measurable disease
  • 0 views
  • 26 Jul, 2021
  • 12 locations